2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More)
Turning $1,000 into $2,400 in five years is no easy feat -- it requires a compound annual growth rate (CAGR) of 19.1%. However, both Regeneron (NASDAQ: REGN) and Moderna (NASDAQ: MRNA) have been able to pull that off (and then some) in the past half decade. Naturally, that doesn't automatically make these biotech stocks worth buying. Past performance isn't a guarantee of future success.
Can Regeneron and Moderna deliver similar returns in the next five years? Let's dig in and find out.
Source Fool.com
Regeneron Pharmaceuticals Inc. Stock
With 47 Buy predictions and 1 Sell predictions Regeneron Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 1091 € shows a slightly positive potential of 1.77% compared to the current price of 1072.0 € for Regeneron Pharmaceuticals Inc..